$ATOS
ATOSSA THERAPEUTICS, INC.

2024 Q2 Form 10-Q Financial Statement

#000095017024058244 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.552M $3.232M $3.590M
YoY Change -13.11% -9.97% 10.5%
% of Gross Profit
Research & Development $3.553M $3.748M $3.508M
YoY Change -4.1% 6.84% 134.02%
% of Gross Profit
Depreciation & Amortization $4.000K $5.000K $3.000K
YoY Change 33.33% 66.67% 50.0%
% of Gross Profit
Operating Expenses $7.105M $6.980M $7.098M
YoY Change -8.83% -1.66% 49.53%
Operating Profit -$7.105M -$6.980M -$7.098M
YoY Change -8.83% -1.66% 49.53%
Interest Expense $1.073M $1.138M $821.0K
YoY Change 9.16% 38.61% -2931.03%
% of Operating Profit
Other Income/Expense, Net -$17.00K -$36.00K -$33.00K
YoY Change -43.33% 9.09% -15.38%
Pretax Income -$6.049M -$5.878M -$6.281M
YoY Change -38.46% -6.42% 31.24%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.049M -$5.900M -$6.281M
YoY Change -38.46% -6.07% 31.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.05 -$0.05
Diluted Earnings Per Share -$0.05 -$0.05 -$0.05
COMMON SHARES
Basic Shares Outstanding 125.8M 125.3M 126.6M
Diluted Shares Outstanding 125.7M 125.3M 126.6M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.53M $83.96M $103.9M
YoY Change -19.99% -19.17% -21.0%
Cash & Equivalents $79.50M $84.00M $103.9M
Short-Term Investments
Other Short-Term Assets $2.192M $3.095M $858.0K
YoY Change 31214.29% 260.72% 20.85%
Inventory
Prepaid Expenses $987.0K $1.613M $5.295M
Receivables
Other Receivables
Total Short-Term Assets $81.72M $87.06M $110.9M
YoY Change -22.91% -21.48% -18.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.710M $1.710M $4.700M
YoY Change 0.0% -63.62%
Other Assets $2.430M $2.322M $631.0K
YoY Change 278.5% 267.99% 0.16%
Total Long-Term Assets $4.140M $4.032M $5.331M
YoY Change 76.02% -24.37% 746.19%
TOTAL ASSETS
Total Short-Term Assets $81.72M $87.06M $110.9M
Total Long-Term Assets $4.140M $4.032M $5.331M
Total Assets $85.86M $91.09M $116.2M
YoY Change -20.76% -21.61% -15.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.056M $1.230M $1.444M
YoY Change -10.05% -14.82% -9.52%
Accrued Expenses $1.907M $1.613M $613.0K
YoY Change 137.48% 163.13% 410.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.696M $5.328M $2.944M
YoY Change 63.77% 80.98% 26.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.696M $5.328M $2.944M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.696M $5.328M $2.944M
YoY Change 63.77% 80.98% 26.79%
SHAREHOLDERS EQUITY
Retained Earnings -$198.2M -$192.2M -$162.5M
YoY Change 15.04% 18.27% 21.23%
Common Stock $22.87M $22.83M $275.1M
YoY Change -91.73% -91.7% 2.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.16M $85.76M $113.3M
YoY Change
Total Liabilities & Shareholders Equity $85.86M $91.09M $116.2M
YoY Change -20.76% -21.61% -15.48%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$6.049M -$5.900M -$6.281M
YoY Change -38.46% -6.07% 31.26%
Depreciation, Depletion And Amortization $4.000K $5.000K $3.000K
YoY Change 33.33% 66.67% 50.0%
Cash From Operating Activities -$4.531M -$4.700M -$7.022M
YoY Change 1.48% -33.07% 43.95%
INVESTING ACTIVITIES
Capital Expenditures $3.000K $6.000K $0.00
YoY Change -76.92% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$9.000K
YoY Change
Cash From Investing Activities -$3.000K -$6.000K $0.00
YoY Change -76.92% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 100.0K 204.0K $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -4.531M -4.700M -$7.022M
Cash From Investing Activities -3.000K -6.000K $0.00
Cash From Financing Activities 100.0K 204.0K $0.00
Net Change In Cash -4.434M -4.500M -$7.022M
YoY Change -0.98% -35.92% 43.57%
FREE CASH FLOW
Cash From Operating Activities -$4.531M -$4.700M -$7.022M
Capital Expenditures $3.000K $6.000K $0.00
Free Cash Flow -$4.534M -$4.706M -$7.022M
YoY Change 1.25% -32.98% 43.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001488039
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-35610
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ATOSSA THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4753208
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
107 Spring Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98104
CY2024Q1 dei City Area Code
CityAreaCode
206
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
588-0256
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.18 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
ATOS
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
125757416
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83960000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88460000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000
CY2024Q1 atos Prepaid Materials
PrepaidMaterials
1372000
CY2023Q4 atos Prepaid Materials
PrepaidMaterials
1487000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1613000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2162000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
87055000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
92219000
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1710000
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
1710000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2322000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2323000
CY2024Q1 us-gaap Assets
Assets
91087000
CY2023Q4 us-gaap Assets
Assets
96252000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1230000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
806000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1613000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
973000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
659000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1826000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1803000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5328000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5236000
CY2024Q1 us-gaap Liabilities
Liabilities
5328000
CY2023Q4 us-gaap Liabilities
Liabilities
5236000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
582
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
582
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
582
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
582
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125507814
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125507814
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125304064
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125304064
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
22829000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22792000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
256571000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
255987000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1320046
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1320046
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1475000
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1475000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192166000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186288000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
85759000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91016000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91087000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96252000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3748000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3508000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3232000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3590000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
6980000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
7098000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6980000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7098000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1138000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
850000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-36000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5878000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6281000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5878000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125319778
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
125319778
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624110
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126624110
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
117964000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1573000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
113256000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91016000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
417000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5878000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
85759000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5878000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6281000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
417000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1573000
CY2024Q1 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-2000
CY2023Q1 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0
CY2024Q1 us-gaap Depreciation
Depreciation
5000
CY2023Q1 us-gaap Depreciation
Depreciation
3000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-115000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-414000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-549000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
108000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
424000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1521000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
640000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-446000
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-995000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-703000
CY2024Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
23000
CY2023Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
46000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4698000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7022000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
204000
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
204000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4500000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7022000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88570000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111000000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84070000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103978000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83960000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103868000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84070000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103978000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTE 1: NATURE OF OPERATIONS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atossa Therapeutics, Inc. (the Company) was incorporated on April 30, 2009, in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is focused on developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-5900000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4700000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84000000
CY2024Q1 atos Working Capital Deficit
WorkingCapitalDeficit
81700000
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain reclassifications have been made to prior period financial information to conform to the current year presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include the valuation of the investment in non-marketable equity securities, stock-based compensation expense, and prepaid or accrued clinical trial balances at the end of any reporting period. Actual results could differ materially from the Company’s estimates.</span>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of deposits of cash and cash equivalents, including those deposited in money market deposit accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any material losses in such accounts and believes it is not exposed to significant risk. The Company has invested its excess cash primarily in money market funds.</span></p>
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 atos Valuation Of Other Investments
ValuationOfOtherInvestments
<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entities</span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews agreements it enters into with third-party entities, pursuant to which the Company may have a variable interest in the entity, in order to determine if the entity is a variable interest entity (VIE). If the entity is a VIE, the Company assesses whether or not it is the primary beneficiary of that entity. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If the Company determines it is the primary beneficiary of a VIE, it consolidates that VIE into the Company’s Condensed Consolidated Financial Statements. The Company’s determination about whether it should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event. The Company currently does not consolidate any VIEs.</span></p>
CY2024Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2023Q1 us-gaap Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
0
CY2024Q1 atos Prepaid Clinical Trial Deposits
PrepaidClinicalTrialDeposits
308000
CY2023Q4 atos Prepaid Clinical Trial Deposits
PrepaidClinicalTrialDeposits
805000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
582000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
794000
CY2024Q1 atos Professional Services Current
ProfessionalServicesCurrent
523000
CY2023Q4 atos Professional Services Current
ProfessionalServicesCurrent
501000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
200000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
62000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1613000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2162000
CY2024Q1 atos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
830000
CY2023Q4 atos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
608000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
783000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
365000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1613000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
973000
CY2024Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
275000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1134000
CY2024Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
234000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
236000
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
150000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
284000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
659000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1654000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1800000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1800000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
417000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1573000
CY2024Q1 atos Balance Includes Other Current Liabilities
BalanceIncludesOtherCurrentLiabilities
26000
CY2023Q4 atos Balance Includes Other Current Liabilities
BalanceIncludesOtherCurrentLiabilities
3000
CY2024Q1 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 atos Stockholder Rights Agreement Number Of Preferred Stock Right Distributed For Each Share Of Common Stock
StockholderRightsAgreementNumberOfPreferredStockRightDistributedForEachShareOfCommonStock
1
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonPercentageOfOwnership
0.15
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonPercentageOfOwnership
0.15
CY2014Q2 atos Stockholder Rights Agreement Acquiring Person Additional Percentage Of Ownership
StockholderRightsAgreementAcquiringPersonAdditionalPercentageOfOwnership
0.02
CY2014Q2 atos Stockholder Rights Agreement Initial Exercise Price Of Each Right
StockholderRightsAgreementInitialExercisePriceOfEachRight
15
CY2014Q2 atos Stockholder Rights Agreement Share Price
StockholderRightsAgreementSharePrice
30
CY2024Q1 atos Consummate A Business Combination Percentage Of Acquired Outstanding Shares
ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares
0.50
CY2024Q1 atos Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power
ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower
0.50
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21310750
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
200000
CY2023Q1 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38975114
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36423050
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17506345
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.79
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
554525
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
145834
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.41
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
269321
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.18
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
880
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
396
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17381978
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.77
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M9D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8351067
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
15321414
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.9
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M25D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6336295
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
17381978
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.77
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M9D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
8351067
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2060564
CY2024Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
CY2024Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06
CY2024Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
77000
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
56000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-058244-index-headers.html Edgar Link pending
0000950170-24-058244-index.html Edgar Link pending
0000950170-24-058244.txt Edgar Link pending
0000950170-24-058244-xbrl.zip Edgar Link pending
atos-20240331.htm Edgar Link pending
atos-20240331.xsd Edgar Link pending
atos-ex31_1.htm Edgar Link pending
atos-ex31_2.htm Edgar Link pending
atos-ex32_1.htm Edgar Link pending
atos-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img96389207_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
atos-20240331_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable